Millendo Therapeutics Announces Acquisition of Alizé Pharma SAS to Expand Orphan Endocrinology Pipeline
– Alizé lead drug candidate, livoletide, has reported positive Phase 2 clinical trial results in Prader-Willi Syndrome (PWS) –
– Leverages Millendo’s expertise to address unmet patient needs in rare endocrine diseases –
ANN ARBOR, Mich. and LYON, France, December 20, 2017 – Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that it has acquired Alizé Pharma SAS in a stock-based transaction.
“The acquisition of Alizé Pharma SAS transforms Millendo into an innovative endocrinology company with two first-in-class, late-stage clinical assets and a presence in both the United States and Europe. With livoletide, we have acquired a promising asset that has demonstrated encouraging efficacy and tolerability in a Phase 2 clinical trial in PWS,” said Julia C. Owens, Ph.D., President and Chief Executive Officer, Millendo Therapeutics. “Alizé Pharma’s research and development operations complement our existing expertise in developing novel treatments for orphan endocrine indications. Together with our on-going nevanimibe (ATR-101) program, which recently reported positive topline Phase 2 results in classic congenital adrenal hyperplasia, we continue to grow our leadership in the endocrinology space by advancing these promising new therapies. We look forward to sharing more details during our presentation at the J.P. Morgan Healthcare Conference next month.”
Actualités - 14/06/2022
Articles de presse - 10/05/2022
Actualités - 10/05/2022